Literature DB >> 21603900

Multiple mutations in the Kras gene in colorectal cancer: review of the literature with two case reports.

Mariana Petaccia Macedo1, Louise De Brot Andrade, Renata Coudry, Rodrigo Crespo, Marina Gomes, Bianca Cristina Garcia Lisboa, Samuel Aguiar, Fernando Augusto Soares, Dirce Maria Carraro, Isabela Werneck Cunha.   

Abstract

PURPOSE: Kras mutations are negative predictors of anti-EGFR therapy, occurring in 40% of colorectal carcinomas (CRCs). Point substitutions in codon 12 or 13 are the most frequent mutations in Kras, but multiple mutations (MMs) in other codons can also develop. Few data exist on MMs with regard to their frequency and the codons and amino acids that are affected. We report two cases of Kras double mutations in codons 12 and 13 and review Kras MMs in primary CRC in PubMed databases. CASE REPORT: A 53-year-old woman and a 70-year-old man presented with deep, invasive, moderately differentiated CRC at an advanced clinical stage. The former had regional lymph node involvement and vaginal wall neoplastic implantation, and the latter had liver metastasis. Primary tumors were examined for Kras mutations by pyrosequencing, which were confirmed by direct sequencing. Both tumors had a mutation in codons 12 and 13, wherein codon 12 was mutated to GAT, and codon 13 became GAC.
CONCLUSIONS: We identified 69 reported cases of Kras MMs and reported two other cases, representing 2.1% of all mutated tumors; the incidence of such mutations is 1.0% in CRC patients. In most cases (59%), MMs develop in a single codon, usually codon 12. Codons 12 and 13 are affected simultaneously in only 27% of cases. These findings add information about the impact of specific amino acid changes in the Kras gene.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21603900     DOI: 10.1007/s00384-011-1238-0

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  35 in total

1.  Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study.

Authors:  W S Samowitz; K Curtin; D Schaffer; M Robertson; M Leppert; M L Slattery
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-11       Impact factor: 4.254

2.  Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

Authors:  Wendy De Roock; Derek J Jonker; Federica Di Nicolantonio; Andrea Sartore-Bianchi; Dongsheng Tu; Salvatore Siena; Simona Lamba; Sabrina Arena; Milo Frattini; Hubert Piessevaux; Eric Van Cutsem; Chris J O'Callaghan; Shirin Khambata-Ford; John R Zalcberg; John Simes; Christos S Karapetis; Alberto Bardelli; Sabine Tejpar
Journal:  JAMA       Date:  2010-10-27       Impact factor: 56.272

3.  Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.

Authors:  H J Andreyev; A R Norman; D Cunningham; J R Oates; P A Clarke
Journal:  J Natl Cancer Inst       Date:  1998-05-06       Impact factor: 13.506

Review 4.  Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives.

Authors:  J P Spano; R Fagard; J-C Soria; O Rixe; D Khayat; G Milano
Journal:  Ann Oncol       Date:  2005-02       Impact factor: 32.976

5.  New comprehensive denaturing-gradient-gel- electrophoresis assay for KRAS mutation detection applied to paraffin-embedded tumours.

Authors:  V M Hayes; J L Westra; E Verlind; W Bleeker; J T Plukker; R M Hofstra; C H Buys
Journal:  Genes Chromosomes Cancer       Date:  2000-12       Impact factor: 5.006

6.  Prevalence of G-to-T transversions among K-ras oncogene mutations in human colorectal tumors in Yugoslavia.

Authors:  N Urosević; K Krtolica; A Skaro-Milić; S Knezević-Usaj; A Dujić
Journal:  Int J Cancer       Date:  1993-05-08       Impact factor: 7.396

7.  Mutations in epidermal growth factor receptor and K-ras in Chinese patients with colorectal cancer.

Authors:  Zuo Yunxia; Cao Jun; Zhu Guanshan; Lu Yachao; Zhou Xueke; Li Jin
Journal:  BMC Med Genet       Date:  2010-02-26       Impact factor: 2.103

8.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Authors:  Rafael G Amado; Michael Wolf; Marc Peeters; Eric Van Cutsem; Salvatore Siena; Daniel J Freeman; Todd Juan; Robert Sikorski; Sid Suggs; Robert Radinsky; Scott D Patterson; David D Chang
Journal:  J Clin Oncol       Date:  2008-03-03       Impact factor: 44.544

9.  KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.

Authors:  Antoine Italiano; Isabelle Hostein; Isabelle Soubeyran; Thibault Fabas; Daniel Benchimol; Serge Evrard; Jean Gugenheim; Yves Becouarn; René Brunet; Marianne Fonck; Eric François; Marie-Christine Saint-Paul; Florence Pedeutour
Journal:  Ann Surg Oncol       Date:  2010-01-05       Impact factor: 5.344

Review 10.  Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.

Authors:  Alberto Bardelli; Salvatore Siena
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544

View more
  13 in total

1.  Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.

Authors:  David T W Jones; Barbara Hutter; Natalie Jäger; Andrey Korshunov; Marcel Kool; Hans-Jörg Warnatz; Thomas Zichner; Sally R Lambert; Marina Ryzhova; Dong Anh Khuong Quang; Adam M Fontebasso; Adrian M Stütz; Sonja Hutter; Marc Zuckermann; Dominik Sturm; Jan Gronych; Bärbel Lasitschka; Sabine Schmidt; Huriye Seker-Cin; Hendrik Witt; Marc Sultan; Meryem Ralser; Paul A Northcott; Volker Hovestadt; Sebastian Bender; Elke Pfaff; Sebastian Stark; Damien Faury; Jeremy Schwartzentruber; Jacek Majewski; Ursula D Weber; Marc Zapatka; Benjamin Raeder; Matthias Schlesner; Catherine L Worth; Cynthia C Bartholomae; Christof von Kalle; Charles D Imbusch; Sylwester Radomski; Chris Lawerenz; Peter van Sluis; Jan Koster; Richard Volckmann; Rogier Versteeg; Hans Lehrach; Camelia Monoranu; Beate Winkler; Andreas Unterberg; Christel Herold-Mende; Till Milde; Andreas E Kulozik; Martin Ebinger; Martin U Schuhmann; Yoon-Jae Cho; Scott L Pomeroy; Andreas von Deimling; Olaf Witt; Michael D Taylor; Stephan Wolf; Matthias A Karajannis; Charles G Eberhart; Wolfram Scheurlen; Martin Hasselblatt; Keith L Ligon; Mark W Kieran; Jan O Korbel; Marie-Laure Yaspo; Benedikt Brors; Jörg Felsberg; Guido Reifenberger; V Peter Collins; Nada Jabado; Roland Eils; Peter Lichter; Stefan M Pfister
Journal:  Nat Genet       Date:  2013-06-30       Impact factor: 38.330

2.  Isolated vaginal metastasis from stage I colon cancer: A case report.

Authors:  Soon Keun Kwon; Chang Sik Yu; Shin-Wha Lee; Jihun Kim; Inho Song; Jong Lyul Lee; Chan Wook Kim; Yong Sik Yoon; In Ja Park; Seok-Byung Lim; Jin Cheon Kim
Journal:  World J Clin Cases       Date:  2020-02-06       Impact factor: 1.337

3.  Epidermal growth factor receptor (EGFR), KRAS, and BRAF mutations in lung adenocarcinomas: A study from India.

Authors:  Varsha Singh; Prerna Guleria; Prabhat Singh Malik; Anant Mohan; Sanjay Thulkar; R M Pandey; Kalpana Luthra; Sudheer Arava; Ruma Ray; Deepali Jain
Journal:  Curr Probl Cancer       Date:  2018-12-17       Impact factor: 3.187

4.  Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients.

Authors:  Grigoriy A Yanus; Anna V Belyaeva; Alexandr O Ivantsov; Ekatherina Sh Kuligina; Evgeny N Suspitsin; Natalia V Mitiushkina; Svetlana N Aleksakhina; Aglaya G Iyevleva; Olga A Zaitseva; Olga S Yatsuk; Tatiana V Gorodnova; Tatiana N Strelkova; Sofia A Efremova; Alla Yu Lepenchuk; Altn N Ochir-Garyaev; Moisey B Paneyah; Dmitriy E Matsko; Alexandr V Togo; Evgeny N Imyanitov
Journal:  Med Oncol       Date:  2013-08-14       Impact factor: 3.064

5.  Silencing of Oncogenic KRAS by Mutant-Selective Small Interfering RNA.

Authors:  Bjoern Papke; Salma H Azam; Anne Y Feng; Christina Gutierrez-Ford; Hayden Huggins; Pradeep S Pallan; Amanda E D Van Swearingen; Martin Egli; Adrienne D Cox; Channing J Der; Chad V Pecot
Journal:  ACS Pharmacol Transl Sci       Date:  2021-02-04

6.  RAS mutations vary between lesions in synchronous primary colorectal cancer: testing only one lesion is not sufficient to guide anti-EGFR treatment decisions.

Authors:  Mariana Petaccia de Macedo; Fernanda Machado de Melo; Júlia da Silva Ribeiro; Celso Abdon Lopes de Mello; Maria Dirlei Ferreira de Souza Begnami; Fernando Augusto Soares; Dirce Maria Carraro; Isabela Werneck da Cunha
Journal:  Oncoscience       Date:  2015-02-09

7.  K-ras Mutation in Colorectal Cancer, A Report from Southern Iran.

Authors:  Navid Omidifar; Bita Geramizadeh; Mitra Mirzai
Journal:  Iran J Med Sci       Date:  2015-09

8.  KRAS mutation analysis by PCR: a comparison of two methods.

Authors:  Louise Bolton; Anne Reiman; Katie Lucas; Judith Timms; Ian A Cree
Journal:  PLoS One       Date:  2015-01-08       Impact factor: 3.240

9.  Coexistence of two different mutations in codon 12 of the Kras gene in colorectal cancer: Report of a case supporting the concept of tumoral heterogeneity.

Authors:  Giuseppina Improta; Angela Zupa; Luciana Possidente; Alfredo Tartarone; Piernicola Pedicini; Antonio Nappi; Sergio Molinari; Filippo Fraggetta; Giulia Vita
Journal:  Oncol Lett       Date:  2013-03-14       Impact factor: 2.967

10.  Circulating tumor DNA in patients with colorectal adenomas: assessment of detectability and genetic heterogeneity.

Authors:  Ni Ni Moe Myint; Ajay M Verma; Daniel Fernandez-Garcia; Panchali Sarmah; Patrick S Tarpey; Saif Sattar Al-Aqbi; Hong Cai; Ricky Trigg; Kevin West; Lynne M Howells; Anne Thomas; Karen Brown; David S Guttery; Baljit Singh; Howard J Pringle; Ultan McDermott; Jacqui A Shaw; Alessandro Rufini
Journal:  Cell Death Dis       Date:  2018-08-30       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.